FGF21 and metabolic dysfunction-associated steatotic liver disease: Compared with other potential NAFLD/NASH drugs, apart from the effects on the pathological characteristics of NAFLD/NASH itself, FGF21 also delivers improvements in whole-body metabolism and cardiovascular risk profile, as mentioned above.